Md. biopharm shows profit, continues studies of cancer drug

Rexahn Pharmaceuticals Inc., a Rockville biopharmaceutical company, had a profit in its second quarter because of accounting adjustments resulting from a change in stock price. Taking into account an upward adjustment of $5.5 million in an unrealized gain on the fair value of warrants, Rexahn's profit was just under $1 million in the quarter, or 4 cents ...

To purchase a reprint of this article, contact reprints@thedailyrecord.com.